Phage Resistance in Multidrug-Resistant Klebsiella pneumoniae ST258 Evolves via Diverse Mutations That Culminate in Impaired Adsorption
Author(s) -
Shayla Hesse,
Manoj Rajaure,
Erin Wall,
Joy Johnson,
Valery Bliskovsky,
Susan Gottesman,
Sankar Adhya
Publication year - 2020
Publication title -
mbio
Language(s) - English
Resource type - Journals
eISSN - 2161-2129
pISSN - 2150-7511
DOI - 10.1128/mbio.02530-19
Subject(s) - lytic cycle , phage therapy , bacteriophage , mutant , phagemid , klebsiella pneumoniae , microbiology and biotechnology , biology , gene , phage display , multiple drug resistance , virology , drug resistance , genetics , escherichia coli , virus , antibody
The therapeutic use of bacteriophage (phage) is garnering renewed interest in the setting of difficult-to-treat infections. Phage resistance is one major limitation of phage therapy; therefore, developing effective strategies to avert or lessen its impact is critical. Characterization ofin vitro phage resistance may be an important first step in evaluating the relative likelihood with which phage-resistant populations emerge, the most likely phenotypes of resistant mutants, and the effect of certain phage cocktail combinations in increasing or decreasing the genetic barrier to resistance. If this information confers predictive powerin vivo , then routine studies of phage-resistant mutants and theirin vitro evolution should be a valuable means for improving the safety and efficacy of phage therapy in humans.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom